Regulation of feedback between protein kinase a and the proteasome system worsens huntington's disease

Molecular and Cellular Biology

Volumn 33, Issue 5, 2013, Pages 1073-1084

  Lin, Jiun Tsai ^a   Chang, Wei Cheng ^a   Chen, Hui Mei ^a   Lai, Hsing Lin ^a   Chen, Chih Yeh ^a   Tao, Mi Hua ^a   Chern, Yijuang ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MUTANT PROTEIN; PROTEASOME; RPT6 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUNTINGTON CHOREA; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL LINE; CORPUS STRIATUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MOTOR ACTIVITY; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS;

EID: 84874713556     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01434-12     Document Type: Article

References (56)

1. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
2. Martin JB, Gusella JF. 1986. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 315:1267-1276.
3. Krobitsch S, Kazantsev AG. 2011. Huntington's disease: from molecular basis to therapeutic advances. Int. J. Biochem. Cell Biol. 43:20-24.
4. Tai HC, Schuman EM. 2008. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat. Rev. Neurosci. 9:826-838.
5. Wang XH, Zhang L, Mitch WE, LeDoux JM, Hu J, Du J. 2010. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J. Biol. Chem. 285:21249-21257.
6. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE. 2003. O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115:715-725.
7. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. 2007. Global changes to the ubiquitin system in Huntington's disease. Nature 448:704-708.
8. Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ. 2008. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol. 180:1177-1189.
9. Hunter JM, Lesort M, Johnson GV. 2007. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res. 85:1774-1788.
10. Chiang MC, Lee YC, Huang CL, Chern Y. 2005. cAMP-response element- binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 280:14331-14340.
11. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. 2010. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 5:e13417. doi:10.1371/journal.pone.0013417.
12. Hebb AL, Robertson HA, Denovan-Wright EM. 2004. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967-981.
13. Andremont A, Lancar R, An Le N, Hattchouel JM, Baron S, Tavakoli T, Daniel MF, Tancrede C, L MG. 1996. Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral center between 1975 and 1989. Clin. Microbiol. Infect. 1:160-167.
14. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:397-407.
15. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y. 2005. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93:310-320.
16. Ehrlich ME, Conti L, Toselli M, Taglietti L, Fiorillo E, Taglietti V, Ivkovic S, Guinea B, Tranberg A, Sipione S, Rigamonti D, Cattaneo E. 2001. ST14A cells have properties of a medium-size spiny neuron. Exp. Neurol. 167:215-226.
17. Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH, Dickson DW, Chern Y. 2008. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J. Neurosci. 28:3277-3290.
18. Liu FC, Wu GC, Hsieh ST, Lai HL, Wang HF, Wang TW, Chern Y. 1998. Expression of type VI adenylyl cyclase in the central nervous system: implication for a potential regulator of multiple signals in different neurotransmitter systems. FEBS Lett. 436:92-98.
19. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
20. Kim YC, Wu SY, Lim HS, Chiang CM, Kodadek T. 2009. Nonproteolytic regulation of p53-mediated transcription through destabilization of the activator promoter complex by the proteasomal ATPases. J. Biol. Chem. 284:34522-34530.
21. Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan WS, Arndt K, Frank M, Gordon RE, Gawinowicz MA, Zhao Y, Colman DR. 2001. The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron 32:63-77.
22. Wang YT, Chuang JY, Shen MR, Yang WB, Chang WC, Hung JJ. 2008. Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J. Mol. Biol. 380:869-885.
23. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
24. Chern Y, Lai HL, Fong JC, Liang Y. 1993. Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol. Pharmacol. 44:950-958.
25. Xiao X, McCown TJ, Li J, Breese GR, Morrow AL, Samulski RJ. 1997. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res. 756:76-83.
26. Chen CC, Sun CP, Ma HI, Fang CC, Wu PY, Xiao X, Tao MH. 2009. Comparative study of anti-hepatitis B virus RNA interference by doublestranded adeno-associated virus serotypes 7, 8, and 9. Mol. Ther. 17:352-359.
27. Martire A, Calamandrei G, Felici F, Scattoni ML, Lastoria G, Domenici MR, Tebano MT, Popoli P. 2007. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wildtype mice. Neurosci. Lett. 417:78-83.
28. Hegde AN, Goldberg AL, Schwartz JH. 1993. Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 90:7436-7440.
29. Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ, Kudlow JE. 2007. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem. 282: 22460-22471.
30. Oyler GA, Higgins GA, Hart RA, Battenberg E, Billingsley M, Bloom FE, Wilson MC. 1989. The identification of a novel synaptosomalassociated protein, SNAP-25, differentially expressed by neuronal subpopulations. J. Cell Biol. 109:3039-3052.
31. Rezvani K, Teng Y, Shim D, De Biasi M. 2007. Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity. J. Neurosci. 27:10508-10519.
32. Benito E, Barco A. 2010. CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models. Trends Neurosci. 33:230-240.
33. Asai M, Tsukamoto O, Minamino T, Asanuma H, Fujita M, Asano Y, Takahama H, Sasaki H, Higo S, Asakura M, Takashima S, Hori M, Kitakaze M. 2009. PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J. Mol. Cell. Cardiol. 46:452-462.
34. Huang CL, Yang JM, Wang KC, Lee YC, Lin YL, Yang YC, Huang NK. 2011. Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A(2A) receptor and ubiquitin proteasome system. J. Ethnopharmacol. 138:162-168.
35. Giralt A, Saavedra A, Carreton O, Xifro X, Alberch J, Perez-Navarro E. 2011. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet. 20:4232-4247.
36. Demartino GN, Gillette TG. 2007. Proteasomes: machines for all reasons. Cell 129:659-662.
37. Li X, Wang CE, Huang S, Xu X, Li XJ, Li H, Li S. 2010. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Hum. Mol. Genet. 19:2445-2455.
38. Bett JS, Cook C, Petrucelli L, Bates GP. 2009. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS One 4:e5128. doi:10.1371/journal.pone.0005128.
39. Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP. 2003. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 21:897-902.
40. Ortega Z, Diaz-Hernandez M, Maynard CJ, Hernandez F, Dantuma NP, Lucas JJ. 2010. Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J. Neurosci. 30:3675-3688.
41. Bingol B, Wang CF, Arnott D, Cheng D, Peng J, Sheng M. 2010. Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell 140:567-578.
42. Djakovic SN, Marquez-Lona EM, Jakawich SK, Wright R, Chu C, Sutton MA, Patrick GN. 2012. Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons. J. Neurosci. 32:5126-5131.
43. Hamilton AM, Oh WC, Vega-Ramirez H, Stein IS, Hell JW, Patrick GN, Zito K. 2012. Activity-dependent growth of new dendritic spines is regulated by the proteasome. Neuron 74:1023-1030.
44. Heck N, Betuing S, Vanhoutte P, Caboche J. 2012. A deconvolution method to improve automated 3D-analysis of dendritic spines: application to a mouse model of Huntington's disease. Brain Struct. Funct. 217: 421-434.
45. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS. 2001. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86:2667-2677.
46. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N. 2001. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21:9112-9123.
47. McNaught KS, Jnobaptiste R, Jackson T, Jengelley TA. 2010. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. Synapse (New York) 64: 241-250.
48. Bingol B, Schuman EM. 2004. A proteasome-sensitive connection between PSD-95 and GluR1 endocytosis. Neuropharmacology 47:755-763.
49. Jiang X, Litkowski PE, Taylor AA, Lin Y, Snider BJ, Moulder KL. 2010. A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing. J. Neurosci. 30:1798-1809.
50. Cepeda C, Cummings DM, Hickey MA, Kleiman-Weiner M, Chen JY, Watson JB, Levine MS. 2010. Rescuing the corticostriatal synaptic disconnection in the R6/2 mouse model of Huntington's disease: exercise, adenosine receptors and ampakines. PLoS Curr. 2010:pii RRN1182. doi: 10.1371/currents.RRN1182.
51. Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. 2007. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 81:253-271.
52. Chiang MC, Chen HM, Lai HL, Chen HW, Chou SY, Chen CM, Tsai FJ, Chern Y. 2009. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitinproteasome system. Hum. Mol. Genet. 18:2929-2942.
53. Huang NK, Lin JH, Lin JT, Lin CI, Liu EM, Lin CJ, Chen WP, Shen YC, Chen HM, Chen JB, Lai HL, Yang CW, Chiang MC, Wu YS, Chang C, Chen JF, Fang JM, Lin YL, Chern Y. 2011. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 6:e20934. doi:10.1371/journal.pone.0020934.
54. Lee YC, Yang YC, Huang CL, Kuo TY, Lin JH, Yang DM, Huang NK. 2012. When cytokinin, a plant hormone, meets the adenosine A2A receptor: a novel neuroprotectant and lead for treating neurodegenerative disorders? PLoS One 7:e38865. doi:10.1371/journal.pone.0038865.
55. Mievis S, Blum D, Ledent C. 2011. A(2A) receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 41:570-576.
56. Popoli P, Blum D, Domenici MR, Burnouf S, Chern Y. 2008. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr. Pharm. Des. 14:1500-1511.